Vinva Investment Management Ltd Sells 176 Shares of IDEXX Laboratories, Inc. $IDXX

Vinva Investment Management Ltd trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,789 shares of the company’s stock after selling 176 shares during the quarter. Vinva Investment Management Ltd’s holdings in IDEXX Laboratories were worth $15,827,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Opal Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories during the second quarter worth $29,000. Ameritas Advisory Services LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth $36,000. WPG Advisers LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter valued at about $37,000. Bank of Jackson Hole Trust boosted its holdings in shares of IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after purchasing an additional 69 shares during the last quarter. Finally, NewSquare Capital LLC grew its position in shares of IDEXX Laboratories by 87.5% during the second quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after purchasing an additional 35 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on IDXX. BTIG Research boosted their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. UBS Group lifted their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Piper Sandler reiterated a “neutral” rating and set a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Finally, Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research note on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $730.50.

Insider Buying and Selling

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 1.4%

Shares of IDXX opened at $755.96 on Thursday. The company has a market cap of $60.36 billion, a PE ratio of 62.94, a P/E/G ratio of 4.06 and a beta of 1.62. The business has a fifty day moving average of $663.01 and a 200 day moving average of $602.29. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the business posted $2.80 earnings per share. The business’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.